not used title
not used title
Throughout the course of the past year, discussions surrounding the implementation of the Inflation Reduction Act have dominated health care industry circles, including specific provisions within the law and changes needed to continue fostering medical innovation. I recently had the opportunity to sit down with one of our PhRMA board members, Mark Reisenauer, President, Astellas US to discuss promising treatments and the policy reforms that are needed to ensure this critical research and development can continue.
Steve Ubl (SU): Can you touch on some of Astellas' emerging developments from a treatment perspective that you are most excited about?
Mark Reisenauer (MR): One area that I would say we, as a company, are most excited about is our expanding portfolio of approved and investigational cancer therapies. We remain highly focused on growing the scope and utility of our oncology portfolio and pipeline.
For example, last year we had the opportunity to present positive results from our Phase 3 GLOW trial, evaluating the efficacy and safety of a monoclonal antibody for use in patients with a type of stomach cancer called CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. Stomach cancer is the fifth most diagnosed cancer worldwide, which is why advances like this are so critical.
We also were thrilled to join our partner Pfizer in gaining FDA approval for the combined use of two medicines to treat advanced bladder cancer. Phase 3 data demonstrated that combination nearly doubled the median overall survival for patients compared to chemotherapy.
In addition, Astellas, also in partnership with Pfizer, announced Phase 3 clinical trial data showing our advanced prostate cancer medicine in combination with another drug lowered the risk of metastasis by 58% in patients with non-metastatic hormone-sensitive prostate cancer. Prostate cancer is the most commonly diagnosed cancer in men, after skin cancer.
For these cancers and others, our goal is to pioneer first-in-class treatments that reshape standards of care and help change the course of cancer treatment for patients.
SU: One issue that continues to garner robust bipartisan and public support is pharmacy benefit manager (PBM) reform. What is your primary concern with the way PBMs are allowed to operate, and what changes can be instituted to ensure patients have access to their medicines at the pharmacy counter?
MR: Here in Astellas’ home state of Illinois, we’ve seen policymakers working to rein in PBMs and put patients first. Governor Pritzker created the state’s first comprehensive regulatory framework for PBMs back in 2019, which has already made a difference in helping patients access their medicines and avoid surprises at the pharmacy counter.
This was an important first step, and we are encouraged to see strong momentum across the states to address PBM tactics and protect patients. However, there is more to be done in the states and at the federal level.
Our primary concern is the lack of transparency and accountability that has allowed PBMs to operate in a black box and raise costs for consumers. PBMs are excluding lower-cost medications from formularies and overcharging patients for medicines they need — all while generating record profits. It’s also vital that compensation for services provided by PBMs be based on a fixed fee, rather than the list price of a medicine (a proposal often referred to as delinking). This will help reduce misaligned incentives in the system.
It’s clear that something needs to be done, and we look forward to further action from policymakers and regulators.
SU: There has been a lot of talk lately about the Inflation Reduction Act's impact on patients' ability to access new and innovative medical treatments. What fixes are needed to the law to help protect patient access to the care they need?
MR: Unfortunately, the Inflation Reduction Act (IRA) is an example of federal policy that may have been well meaning, but will have unintended consequences. As I mentioned, one of Astellas’ primary focus areas is oncology, including medicines targeting prostate, leukemia and bladder cancers. For a mid-sized company like us — and for the patients who rely on our cancer medicines — the IRA’s impacts cannot be ignored.
Perhaps the biggest change needed to the IRA is the timeline for price setting of “small-molecule medicines,” or those that typically come in pill or tablet form. The majority of cancer medicines approved by the FDA are small-molecule medicines, yet the IRA disincentivizes their development. By permitting the selection of these medicines for price setting after just nine years after FDA approval — far earlier than the 13 years post approval for biologic medicines — the IRA will discourage companies from investing in these medicines.
Expanding the number of cancers or stages of disease a medicine can treat takes years of additional clinical research after initial FDA approval.
I referenced earlier our Phase 3 prostate cancer trial (called EMBARK). This research comes 11 years after our oral drug was first approved for one form of advanced prostate cancer.
The trial was scheduled to last four years, but we decided to extend it because we believed in the science. Now, eight years later, these data supported the recent FDA approval of our medicine to treat more prostate cancer patients in earlier stages of the disease.
Under IRA, the business case and ability to invest additional resources and time becomes much more difficult.
We need legislative fixes to ensure companies can make these challenging investment decisions. At the same time, we also need better transparency and predictability in the implementation of the IRA as it currently stands.
SU: The Biden Administration recently unveiled a proposal to give federal agencies the power to take patents away from private companies if they don’t like the prices those companies charge for innovations resulting from any amount of government collaboration. What effect could this announcement on “march-in” rights have on the type of R&D you just described?
MR: The proposed “march-in” framework would deter R&D collaboration between the private sector, academia and the federal government, and discourage the development of future innovative products. And this wouldn’t affect just medicines, but would extend to other technology fields involving government-funded basic research, such as agriculture, clean energy, computer science and AI.
It’s well known that the prostate cancer medicine I mentioned earlier has been in this spotlight, with calls to invoke “march-in” rights on the product being rejected on multiple occasions.
The fact is, this medicine is a prime example of how collaboration between early-stage public research and private development can benefit American consumers — as the Bayh-Dole Act envisioned.
A small amount of government funding helped with the compound’s initial discovery. Astellas and its partners then invested more than $2.3 billion in R&D over more than a decade – with meaningful results for prostate cancer patients, including those announced last year.
Not only would the proposed framework chill the licensing agreements between academia and private companies that are crucial to taking an idea from the lab to the patient, it is hard to fathom a company committing such sustained investments with the knowledge that the product’s patent could be seized by the government at any time.
The U.S. has thrived as an innovation leader because our ecosystem emboldens collaboration and risk-taking. We need to embrace these assets — and work together to fix the true problems in our system that make medicines inaccessible and unaffordable for patients.
Learn more about how our industry is working to improve access and affordability here.
Stephen J. Ubl
Stephen J. Ubl is president and chief executive officer of the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents America’s leading biopharmaceutical research companies. The U.S. biopharmaceutical sector directly employs more than 800,000 Americans and invests more than $100 billion in research and development annually – more than any other industry in America.
Ubl leads PhRMA’s work preserving and strengthening a health care and economic environment that encourages medical innovation, new drug discovery and access to life-saving medicines. Ubl is recognized around the world as a leading health care advocate and policy expert who collaborates successfully with diverse stakeholder groups – including patient and physician groups, regulators, public and private payers, and global trade organizations – to help ensure timely patient access to innovative treatments and cures. The New York Times writes, “If anyone can find areas of agreement with the critics, or at least work productively with them, it may be Mr. Ubl. He is more conversant with the intricacies of health policy, and more adept at the politics."
Previously, Ubl served as president and CEO of medical technology association AdvaMed, where he helped facilitate landmark reforms related to the U.S. Food and Drug Administration product review process and Medicare’s coverage and reimbursement of medical technologies. He led the industry’s defense of breakthrough R&D, successfully delaying an innovation-stifling device tax, and, in 2013, was recognized by a leading industry publication as one of 10 people to have a lasting impact on the medical technology industry.
Ubl has worked extensively with patient advocacy organizations in health policy, including longstanding service on the board of the National Health Council, a leading umbrella organization for voluntary health care organizations and has been personally involved with JDRF (formerly known as the Juvenile Diabetes Research Foundation).
He is routinely recognized as one of Washington’s most effective advocates. Ubl has been recognized on Business Insider’s “DC Healthcare Power Players” and Modern Healthcare’s “100 Most Influential People in Healthcare.” He is identified as a top health influencer by Medical Marketing & Media and PR Week magazines.
https://x.com/steveubl
https://www.linkedin.com/in/steveubl/
President and Chief Executive Officer
New poll: 2 in 3 voters prefer a candidate committed to lowering health insurance premiums
September 18, 2026
Bayh-Dole: The fuel for America’s innovation engine
September 2, 2026
What AARP isn’t telling seniors about MFN
August 24, 2026
Policymakers should improve patient access and reject price controls
August 18, 2026
CMS proposal could discourage patient-centered innovation
August 18, 2026
ICYMI: Biopharmaceutical companies in America hit new investment milestone
August 14, 2026
Nearly 1 in 4 patients initially denied access to IRA medicines
August 6, 2026
Voters continue to voice their concerns on government price controls
July 24, 2026
Medicare Part D at 20: Building on a strong foundation
July 23, 2026
Setting the record straight: 3 facts about drug patents
July 13, 2026
New PBM principles don't change the fundamental challenge: Access to lower-cost medicines
July 10, 2026
Staffing up: Building the future biopharma workforce to keep America in the lead
June 29, 2026
Guest Blog: Price controls won’t lower costs when insurers control access
June 25, 2026
World Sickle Cell Day: Recognizing the promise of gene therapy
June 19, 2026
MFN could disrupt the affordable medicines patients depend on
June 18, 2026
New “America Cures” ad: U.S. patients get new medicines first
June 15, 2026
Nearly 80 researchers advocate on Capitol Hill
June 11, 2026
Patients speak out: MFN won't address my affordability concerns
June 4, 2026
Intellectual Property and Hatch-Waxman: A blueprint for American leadership and patient savings
June 2, 2026
MFN price controls threaten American jobs and the U.S. economy
May 28, 2026
America's cancer research progress is real and worth protecting
May 28, 2026
Ahead of ASCO: Cancer innovation is promising, but policy choices matter
May 26, 2026
State price-setting boards create more questions than answers
May 20, 2026
New analysis highlights access to new medicines in the United States and abroad
May 13, 2026
MFN won’t lower costs when insurers call the shots
May 8, 2026
Guest Blog: How MFN price controls could decide my health care
April 30, 2026
MFN price controls would drain pensions and put retirements at risk
April 23, 2026
States should avoid repeating the IRA’s price‑setting mistakes
April 21, 2026
CMS undermines medical progress with MFN price controls
April 16, 2026
Trump Administration’s efforts to have other countries pay their fair share are underway
April 15, 2026
CMS’ MFN proposals won’t help seniors despite lofty promises
April 9, 2026
Voters voice concerns on government price controls
April 7, 2026
Virginia should be cautious about importing federal price-setting mechanisms
April 1, 2026
Policymakers shouldn’t double down on the IRA’s flaws with MFN
March 30, 2026
Argentina sets course to enable innovation by rejecting failed patent rules
March 26, 2026
16 years later: How BPCIA continues to expand competition and lower costs
March 23, 2026
Key context is often missing from the debate over the Patent Trial and Appeal Board
March 20, 2026
How AI is transforming the drug innovation lifecycle
March 19, 2026
MFN drug pricing risks reviving a harmful metric the U.S. rejected
March 16, 2026
Leadership in biopharmaceutical R&D provides U.S. patients the greatest access to innovative medicines
March 11, 2026
Harmful U.S. policies will help drive China’s global leadership in biopharmaceutical innovation
March 4, 2026
MFN undermines U.S. biopharmaceutical innovation
February 25, 2026
CMS puts patients and innovation at risk with MFN
February 24, 2026
Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs
February 2, 2026
Congratulations to our 2026 Working for Cures Employee Champions
January 29, 2026
New list of selected drugs highlights growing consequences of government price setting
January 28, 2026
Price setting policies put cancer gains in jeopardy
January 16, 2026
How post-approval innovation keeps delivering for patients
December 9, 2025
Myth vs. Fact: How government price setting impacts innovation
November 24, 2025
The IRA’s price setting doesn’t guarantee lower costs or better access
November 17, 2025
PhRMA calls on USTR to ensure foreign nations pay their fair share
November 4, 2025
What seniors can expect this open enrollment
October 14, 2025
Three things to know about Bayh-Dole: Innovation that pays off for taxpayers
October 9, 2025
Part D premiums are going up, while choices are going down
October 8, 2025
Manufacturing U.S. jobs and breakthroughs
October 6, 2025
Historic biopharmaceutical investments: A prescription for America’s future
September 29, 2025
Why states struggle to deliver savings: Middlemen and 340B siphon dollars from patients and states
September 15, 2025
Delivering breakthroughs and lower costs for patients
September 8, 2025
Celebrating 60 Years of Medicare
July 30, 2025
PBMs, not patents, are blocking access to lower-cost medicines
July 23, 2025
Medicare patients face higher drug costs, despite IRA promises
July 22, 2025
Bringing to life the full story of biopharmaceutical innovation and investments
July 22, 2025
New report: How intellectual property drives U.S. innovation and biopharma's impact
June 30, 2025
CMS continues to make a bad law worse
June 27, 2025
ICYMI: Forget Foreign Price Controls: There’s a better solution to lowering drug prices
June 26, 2025
What to know about vaccine ingredients: Aluminum and thimerosal
June 24, 2025
Americans are paying a 26% freerider tax on medicines because other countries don’t pay their fair share
June 17, 2025
PhRMA Foundation celebrates 60 years of investing in future scientific leaders
June 11, 2025
New report: Post-approval innovation delivers substantial patient benefits
June 2, 2025
New “Balance the Scales” campaign highlights why Americans pay more for prescription medicines
May 21, 2025
Foreign first pricing schemes don’t address why Americans pay more
May 15, 2025
New analysis: Fewer treatments and cures under the IRA’s pill penalty
May 1, 2025
The biopharmaceutical industry is one of the highest contributors to America’s economy among all manufacturers
April 30, 2025
USTR 2025 Special 301 Report corrects course
April 29, 2025
From sound to science: How IP powers innovation in music and hearing
April 25, 2025
How the IRA is impacting the generic drug market
April 8, 2025
3 myths critics get wrong about intellectual property
March 28, 2025
Three reasons Congress should fix the IRA’s pill penalty
March 24, 2025
ICYMI: PhRMA submits comments to White House on artificial intelligence
March 17, 2025
4 things to know on Rare Disease Day
February 28, 2025
Improved treatments continue to lead to declining cancer mortality rates in the U.S.
February 25, 2025
Biopharmaceutical innovation for a healthier America: PhRMA releases new innovation report
February 21, 2025
New policy agenda charts solutions for a healthier America
February 20, 2025
A successful PhRMA Forum highlights our commitment to a healthier America
February 20, 2025
Guest Perspective: Prioritize Innovative Care
February 11, 2025
Preventing and fighting disease: A look at the biopharmaceutical progress made for patients in 2024
February 3, 2025
Virginia, Don't Let Politicians Take Away Your Medicine
January 23, 2025
Patients are losing as government price setting continues
January 17, 2025
PhRMA CEOs Tee Up Next Week's Health Care Conference
January 11, 2025
A new administration poses new opportunities for patient access
December 17, 2024
Recognizing the value of disease prevention with Dr. Len Friedland from GSK
December 12, 2024
Congratulations to our 2024 Working for Cures Employee Champions
December 11, 2024
Post-approval R&D is critical for fighting cancer. The IRA makes it more difficult.
November 13, 2024
CMS needs to do better
November 4, 2024
PhRMA submission calls for USTR to correct course on trade policy, enforcement
October 18, 2024
Is CMS paying attention to the growing access barriers for Medicare patients under the IRA?
October 18, 2024
7 reasons why states shouldn’t copy the IRA’s price setting mistake
October 15, 2024
The importance of partnership: A conversation with Takeda
October 10, 2024
Did the administration consider the importance of blood cancer medicines to patients in price setting process?
October 8, 2024
New Report: Tackling chronic conditions with preventive treatment
September 30, 2024
Did the administration consider the importance of blood clot medicines to patients in the price setting process?
September 25, 2024
40 Years of Hatch-Waxman: How Can We Secure its Legacy?
September 24, 2024
40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?
September 23, 2024
Addressing the mounting threat of antimicrobial resistance
September 23, 2024
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
September 19, 2024
Three ways state drug price setting boards fail patients
September 18, 2024
The Inflation Reduction Act could increase costs and reduce access for millions of seniors
September 17, 2024
Are the IRA’s Part B inflation rebates lowering costs for Medicare patients? No.
September 16, 2024
New research: American biopharmaceutical investment in R&D drives transformational innovation
September 16, 2024
Did the administration consider the importance of autoimmune disease medicines to patients in price setting process?
September 11, 2024
Biden Administration report debunks myths around patent “evergreening” and “thickets”
September 3, 2024
Did the administration consider the value of innovative diabetes medicines in price setting process?
August 28, 2024
How to protect your children’s health this school year
August 22, 2024
What to know about the latest effort to break patents using a legally dubious avenue
August 21, 2024
New survey: Insurers confirm IRA will reduce patient treatment options
August 20, 2024
The unintended consequences of government price setting in Medicare Part D
August 16, 2024
WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation
August 12, 2024
Don’t put the government between patients and their medicines
August 7, 2024
Biosimilars continue to drive market competition and increase savings for seniors
August 6, 2024
Industry-backed STEM programs have supported 111 million students and nearly 183,000 teachers
August 1, 2024
What is the low-income subsidy program and how is it changing?
July 31, 2024
Three things to know about the United Nations’ new HIV/AIDS report
July 31, 2024
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
July 22, 2024
New Report: Vaccines continue to drive improved health outcomes
July 16, 2024
The future of oncology R&D lies in policymakers’ hands
July 8, 2024
PhRMA reiterates concerns with IRA price setting program, urges CMS to mitigate harm
July 3, 2024
More than 60 researchers advocate on Capitol Hill
July 1, 2024
Showcasing the promise of biopharma at ASCO 2024
June 28, 2024
Alzheimer's & Brain Awareness Month: A conversation with Biogen
June 27, 2024
PhRMA launches education campaign on the benefits of America's IP system
June 26, 2024
The IRA could lead to higher out-of-pocket costs for 3.5 million Medicare patients in 2026
June 25, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eisai
June 24, 2024
Alzheimer's & Brain Awareness Month: A conversation with Eli Lilly and Company
June 20, 2024
ICYMI: Health care policy should be driven by patients, not politics
June 10, 2024
ICYMI: Misaligned policies undermine patient access
June 6, 2024
Women’s Health Month: A conversation with Astellas
May 31, 2024
ICYMI: Innovation transforms lives but misguided federal policies threaten patient outcomes
May 30, 2024
How the IRA is more coercive than any European government price setting scheme
May 29, 2024
Experts discuss the value of IP at Senate Judiciary Committee hearing
May 28, 2024
Mental Health Awareness Month: Supporting loved ones and improving mental health in America
May 28, 2024
How government price setting fails to address systemic health care inequities
May 24, 2024
Women’s Health Month: A conversation with Sage
May 23, 2024
World Trade Week 2024: Time for a more ambitious U.S. trade agenda
May 23, 2024
The use of real-world data in drug development
May 13, 2024
Government price-setting boards: Why Minnesota needs to take a better approach
May 9, 2024
New analysis: Accelerated approval pathway is changing lives in underserved communities
April 30, 2024
World IP Day 2024: Supporting an innovative and sustainable future
April 26, 2024
IRA is already negatively impacting access to medicines in Part D
April 25, 2024
Government price setting won’t help patients in Illinois
April 22, 2024
New analysis: Flawed assessments of a medicine’s value jeopardize patient access
April 11, 2024
3 Takeaways from POLITICO’s Health Care Summit
April 3, 2024
World Vaccine Congress: Building on vaccine success
April 1, 2024
The impact of innovative medicines: A caregiver's perspective
March 26, 2024
ICYMI: More evidence of the IRA’s harmful consequences on post-approval research and development
March 25, 2024
Colorado is proof: Too many unanswered questions remain about state government price setting's impact on patients and providers
March 14, 2024
What new cures would mean to families
March 7, 2024
Watch: A conversation with Dr. Mike Ybarra on Rare Disease Day
February 29, 2024
American Heart Month: A nurse’s perspective
February 27, 2024
International meetings hold big implications for Americans and our innovation ecosystem
February 26, 2024
The truth about Nebraska's price setting push
February 13, 2024
Proposed march-in framework would chill American innovation
February 7, 2024
Three things to know about antibody drug conjugates
February 2, 2024
As the administration continues to falsely claim Medicare “negotiation,” keep these points in mind
February 1, 2024
PhRMA 2024 Special 301 submission: USTR needs to support American innovation, global access to medicines
January 31, 2024
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
January 29, 2024
What they are saying: Experts agree that proposed march-in framework would jeopardize innovation
January 25, 2024
Novel treatments and vaccines approved for U.S. patients in 2023 reach five-year high
January 23, 2024
When it comes to the future of innovation, the ball is in policymakers’ court
January 22, 2024
The Biopharmaceutical Industry Still Needs Clarity from the FDA on Orange Book Listings
December 19, 2023
The White House continues to attack American innovation
December 15, 2023
Biosimilars drive savings, but the IRA undermines their development
December 14, 2023
Taking stock of obesity and its costly effects
December 8, 2023
Congratulations to our 2023 Working for Cures Employee Champions
December 6, 2023
Watch: Putting patients front and center for World AIDS Day
November 30, 2023
Biden Administration’s Indo Pacific trade dialogue is a missed opportunity to bolster American exports, innovation
November 29, 2023
Misuse of march-in could stifle innovation
November 27, 2023
New analysis of patient access restrictions in the United Kingdom
November 21, 2023
WHO Pandemic Agreement offers opportunities and risks for American innovators
November 20, 2023
The IRA’s pill penalty threatens the future of oncology R&D
November 16, 2023
Don't close the door on rare disease research
November 13, 2023
New Report: 1,600 cancer treatments and vaccines in clinical development
November 9, 2023
Word of the Month: The Bayh-Dole Act
November 8, 2023
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
November 6, 2023
PhRMA submission: USTR needs more ambition to combat unfair trade barriers
October 24, 2023
R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot
October 18, 2023
Three things economists are saying about the Inflation Reduction Act
October 11, 2023
Celebrating Hispanic Heritage Month at PhRMA
October 11, 2023
4 truths about state government price setting
October 10, 2023
Word of the Month: AMR
September 27, 2023
IRA threatens seniors’ access to robust treatment options
September 26, 2023
It’s PBMs, not patents, blocking competition
September 14, 2023
What you need to know: COVID-19 public health emergency is over, but ideological attacks on IP remain
September 12, 2023
New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients
September 11, 2023
Correcting the record: IRA’s government price setting provisions are unconstitutional
September 8, 2023
IRA changes to Part D risk access to medicines
August 24, 2023
Watch: New video series spotlights advances in biopharmaceutical science
August 24, 2023